TransMedics: Pioneer of Transplantation Technology Defies Short-Seller Attack and Grows Rapidly
Reading Time: 3 minutes
Record revenues despite controversies : TransMedics surpasses all expectations with a quarterly revenue of $121.6 million – a growth of 50% compared to the previous year. Investigation disproves allegations : An independent review found no evidence of fraud while the company continues to invest in innovative transplantation technologies and logistics. The US medical technology company TransMedics (NASDAQ: TMDX) has established itself as a leading player in the field of organ transplantation technology in recent years. The company develops...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
